Disease relevance of Cyclofem

• There were insignificant changes in the systolic and diastolic blood pressure values recorded at follow-up; only one Cyclofem user developed systemic hypertension (160/100 mm Hg) after 6 months of use and was discontinued for that reason [1].
• The most frequently cited problems among Cyclofem users included breast tenderness, abdominal pain, and dysmenorrhea; yet a third of these women opted to stay on Cyclofem at the end of the study [2].
• In conclusion, long-term administration of the injectable contraceptive Cyclofem did not produce adverse alterations in the endometrium as hyperplasia [3].
• Data based on the trial (March 1990-February 1992) indicate that the Cyclofem women complained of dizziness, nausea, bleeding problems, migraine, vomiting, amenorrhea, allergies and hypertension during the use of Cyclofem [4].

High impact information on Cyclofem

• Main reasons for discontinuation included difficulty making clinic visits (45.1% for Cyclofem vs. 40% for Depo-Provera), menstrual changes (14.1% vs. 12.5%) and nonmenstrual problems (15.5% vs. 12.5%) [5].
• There was significant interindividual variation in the pharmacokinetics of MPA after intramuscular injection of Cyclofem [6].
• This would include providing training and updated technical guidelines concerning both Cyclofem and other contraceptives to providers, with an emphasis on technical issues including contraceptive indications and contraindications, re-injection time frames, maintenance of asepsis and the management of side-effects [7].
• A statistically significant decrease (P less than 0.01) occurred in HDL-cholesterol and total serum protein values and a statistically significant increase (P less than 0.01) was observed in hematocrit value of Cycloprovera users only [8].
• The dose of MPA in the monthly injectable CycloProvera could be substantially reduced without loss of effectiveness [9].

Biological context of Cyclofem

• This study evaluated endometrial histology in women using the once-a-month injectable contraceptive Cyclofem for one year or more [3].

Associations of Cyclofem with other chemical compounds

• Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women [6].

Analytical, diagnostic and therapeutic context of Cyclofem

• The objective of this study was to evaluate the return of fertility in women who used Cyclofem as a contraceptive method during the introductory studies conducted in Brazil, Chile, Colombia, and Peru. From these four cohorts, 101 women were eligible for the study [10].
• Cyclofem proved its use-effectiveness (pregnancy rate of 0.03%) and its safety under routine service conditions of family planning facilities in Mexico. The overall life table continuation rate at 1 year was 26.1% [11].
• Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem [12].
• Reports of the phase III clinical trials on four combined progestogen-estrogen once-a-month injectable contraceptives, Deladroxate, Cyclofem, Mesigyna and Chinese Injectable No. 1, are reviewed focussing on efficacy and reasons for discontinuation [13].

References